The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.

Nielsen R, Jorsal A, Tougaard RS, Rasmussen JJ, Schou M, Videbaek L, Gustafsson I, Faber J, Flyvbjerg A, Wiggers H, Tarnow L, Kistorp C

Diabetes, obesity & metabolism12 Aug 2020Cited by 24 (Europe PMC)

PMID32627271DOI10.1111/dom.14135PepBankPUB-32627271

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction, NT-proBNP decreased by 9% with liraglutide compared with placebo at week 24.
In plain wordsIn patients with heart failure and reduced pumping function, liraglutide lowered the heart stress marker NT-proBNP more than placebo.
Peptide
Liraglutide
Outcome
DecreaseNT-proBNP change at week 24
Study
n = 231
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Measurements
NT-proBNP change
−9%
liraglutide vs placebo
Source sentences
Summary
MR-proANP decreased by 12% (P = .002) and NT-proBNP by 9% (P = .009) during liraglutide treatment compared with placebo at week 24.
2 context sentences(design, population, supporting numbers)
Summary · context
(a predefined secondary endpoint)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727102
02HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction, MR-proANP decreased by 12% with liraglutide compared with placebo at week 24.
In plain wordsIn patients with heart failure and reduced pumping function, liraglutide lowered the heart stress marker MR-proANP more than placebo.
Peptide
Liraglutide
Outcome
DecreaseMR-proANP change at week 24
Study
n = 231
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Measurements
MR-proANP change
−12%
liraglutide vs placebo
Source sentences
Summary
In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P = .002)
2 context sentences(design, population, supporting numbers)
Summary · context
compared with placebo at week 24.
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727101
03HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction, liraglutide had no effect on MR-proADM compared with placebo.
In plain wordsIn patients with heart failure and reduced pumping function, liraglutide did not change the marker MR-proADM compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMR-proADM change
Study
n = 231
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no effect of liraglutide on MR-proADM (P = .10)
1 context sentence(design, population, supporting numbers)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727106
04HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction, liraglutide had no effect on copeptin compared with placebo.
In plain wordsIn patients with heart failure and reduced pumping function, liraglutide did not change copeptin levels compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeCopeptin change
Study
n = 231
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no effect of liraglutide on MR-proADM (P = .10) or copeptin (P = .52).
1 context sentence(design, population, supporting numbers)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727107
05HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction and type 2 diabetes, liraglutide decreased MR-proANP by 27% compared with placebo.
In plain wordsIn patients with heart failure and type 2 diabetes, liraglutide lowered the heart stress marker MR-proANP more than placebo.
Peptide
Liraglutide
Outcome
DecreaseMR-proANP change in patients with type 2 diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Measurements
MR-proANP change
−27%
liraglutide vs placebo, type 2 diabetes
Source sentences
Summary
in patients with T2D, liraglutide decreased MR-proANP by 27% (P < .001) and NT-proBNP by 25% (P = .02) compared with placebo, whereas no change was observed in patients without T2D.
1 context sentence(design, population, supporting numbers)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727103
06HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction and type 2 diabetes, liraglutide decreased NT-proBNP by 25% compared with placebo.
In plain wordsIn patients with heart failure and type 2 diabetes, liraglutide lowered the heart stress marker NT-proBNP more than placebo.
Peptide
Liraglutide
Outcome
DecreaseNT-proBNP change in patients with type 2 diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Measurements
NT-proBNP change
−25%
liraglutide vs placebo, type 2 diabetes
Source sentences
Summary
NT-proBNP by 25% (P = .02) compared with placebo, whereas no change was observed in patients without T2D.
1 context sentence(design, population, supporting numbers)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727104
07HumanRandomized controlled trialEfficacy outcome
In patients with heart failure with reduced ejection fraction and without type 2 diabetes, liraglutide did not change MR-proANP or NT-proBNP.
In plain wordsIn patients with heart failure but without type 2 diabetes, liraglutide did not change these heart stress markers.
Peptide
Liraglutide
Outcome
No significant changeMR-proANP and NT-proBNP change in patients without type 2 diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg daily · 24 weeksAs given in this study (human).
Source sentences
Summary
whereas no change was observed in patients without T2D.
1 context sentence(design, population, supporting numbers)
Summary · context
In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D.
Report a problemFND-3262727105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.